An Extension Trial to Trial NN1250-3583 Comparing Safety and Efficacy of NN1250 With Insulin Glargine, Both With Insulin Aspart as Meal-time Insulin, in Type 1 Diabetes (BEGIN: BB T1 LONG)
Latest Information Update: 17 Oct 2021
Price :
$35 *
At a glance
- Drugs Insulin degludec (Primary) ; Insulin aspart; Insulin glargine
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms BEGIN
- Sponsors Novo Nordisk
- 23 May 2013 UKCRN reports trial status as 'active, no longer recruiting' and planned patient number as 15.
- 12 Mar 2013 New trial record